Eli Lilly and Company (NYSE:LLY) announced Tuesday that it will acquire Curevo Inc., LimmaTech Biologics AG and Vaccine Company, Inc. as the drugmaker expands its infectious disease research portfolio.

The acquisitions strengthen Eli Lilly’s strategy of investing in vaccine and prevention technologies aimed at reducing long-term disease risks tied to infections, including neurological disorders, cancer and antimicrobial-resistant bacterial diseases.

“For 150 years, Lilly has advanced medicines to address the world’s most pressing health challenges,” the company said, adding that infectious diseases remain a major source of global morbidity and long-term health complications.

Eli Lilly Targets Long-Term Disease Prevention

Daniel Skovronsky, Lilly’s chief scientific and product officer and president of Lilly Research Laboratories, said the acquisitions support a broader prevention-focused strategy.

“These acquisitions reflect a deliberate strategy to prevent disease at its source rather than treat its consequences,” Skovronsky said. “Decades of evidence now link common infections to diseases that potentially emerge years later, including neurological disease, cancer and infertility.”

Deal Terms And Vaccine Pipeline Expansion

Curevo’s lead candidate, amezosvatein, is a ...